World journal of gastroenterology

How glucagon-like peptide-1 receptor agonists work from blood sugar control to treating multiple body diseases

Updated

Abstract

GLP-1 receptor agonists (GLP-1RAs) may offer therapeutic potential for metabolic dysfunction-associated fatty liver disease.

  • GLP-1RAs are already transforming the management of type 2 diabetes mellitus.
  • They may provide cardiovascular and renal protective effects, particularly in diabetic kidney disease alongside certain medications.
  • There is evidence suggesting potential benefits for bone health in diabetic osteoporosis.
  • GLP-1RAs could have neuroprotective properties that may aid in the treatment of Alzheimer's disease by affecting insulin signaling in neurons.
  • Improvements in hormonal and metabolic profiles in polycystic ovary syndrome have been associated with the use of GLP-1RAs.
  • Ongoing research is necessary to fully understand the broad therapeutic effects of GLP-1RAs across various systemic diseases.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Conflict-of-interest statement: The authors declare that they have no competing interests.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free